Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
News|Articles|July 18, 2023
Alzheimer Disease Pipeline Update: Inside Look at Promising Agents
Author(s)Marco Meglio, Isabella Ciccone, MPH
With the recent approval of lecanemab (Leqembi; Eisai), NeurologyLive took a closer look at the Alzheimer pipeline, and the potential agents clinicians should keep an eye on in the coming years.
Advertisement
Advertisement
There are an estimated 6.3 million individuals with Alzheimer disease (AD) dementia in the United States, and an estimated 50 million individuals with AD dementia globally. These populations are expected to grow to 12.7 million and 150 million in the US and globally, respectively, by 2050. Fortunately, though, in recent years, drug development has expanded significantly, with several dozens of agents currently progressing through the pipeline.
Related to this article
Microstructure Imaging has announced that the FDA cleared its MICSI-PET, an MR-guided PET enhancement platform with automated amyloid Centiloid and tau quantification.
Subgroup analyses from the phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, malaise, and cognition in long COVID patients with more severe baseline symptoms.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The clinical neuropsychologist and assistant professor of medicine at the Icahn School of Medicine at Mount Sinai discussed the mechanisms behind brain fog from Long COVID and its potential links to Alzheimer risk.
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Advertisement
Advertisement